Home » First patient enrolled in Micell Technologies Dessolve II study
First patient enrolled in Micell Technologies Dessolve II study
March 8, 2011
Micell Technologies has enrolled the first patient in the Dessolve II clinical trial (DES with Sirolimus and a bioabsorbable polymer for the treatment of patients with de novo lesions in the native coronary arteries). This trial is supporting CE Mark approval of the company's MiStent Drug-Eluting Coronary Stent System (MiStent DES).
The MiStent DES employs Micell's proprietary supercritical fluid technology, which applies a controlled absorbable polymer-active drug (sirolimus) matrix onto a cobalt-chromium stent. The polymer dissolves and releases the drug into tissue in a controlled manner optimizing dosing throughout the affected artery. MiStent DES aims to minimize in-stent late lumen loss at nine months.
Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials
Learn More Here